CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Aligos Therapeutics, Inc. - ALGS CFD

14.2158
4.67%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.3284
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 13.7058
Open 14.0258
1-Year Change 1658.5%
Day's Range 14.0258 - 14.7658
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 17, 2024 13.7058 -0.4600 -3.25% 14.1658 14.8658 13.5458
Sep 16, 2024 14.2158 0.1800 1.28% 14.0358 14.7958 14.0258
Sep 13, 2024 14.3258 0.6500 4.75% 13.6758 14.9158 13.6758
Sep 12, 2024 13.7358 -0.5600 -3.92% 14.2958 16.2658 13.0958
Sep 11, 2024 13.7258 -0.0400 -0.29% 13.7658 14.5758 13.2358
Sep 10, 2024 13.5980 -4.4000 -24.45% 17.9980 17.9980 12.7280
Sep 9, 2024 18.9980 6.7900 55.62% 12.2080 19.2880 12.0780
Sep 6, 2024 12.0980 0.6200 5.40% 11.4780 12.4380 11.2780
Sep 5, 2024 11.8380 0.4400 3.86% 11.3980 11.9080 11.1980
Sep 4, 2024 11.5480 -0.4400 -3.67% 11.9880 12.0480 11.4780
Sep 3, 2024 11.6980 -0.8000 -6.40% 12.4980 12.4980 11.2980
Aug 30, 2024 12.5080 -0.2700 -2.11% 12.7780 12.9080 12.3880
Aug 29, 2024 13.0480 0.2400 1.87% 12.8080 13.6980 12.7780
Aug 28, 2024 12.7980 0.0000 0.00% 12.7980 13.0980 12.7480
Aug 27, 2024 13.1280 -0.0100 -0.08% 13.1380 13.3480 12.4480
Aug 26, 2024 13.3180 -0.2400 -1.77% 13.5580 13.6780 13.0980
Aug 23, 2024 13.7080 0.2100 1.56% 13.4980 13.7780 13.4980
Aug 22, 2024 13.6980 0.0000 0.00% 13.6980 14.0980 13.1280
Aug 21, 2024 13.7380 -0.1600 -1.15% 13.8980 14.1880 13.3480
Aug 20, 2024 14.2380 0.2300 1.64% 14.0080 14.3780 13.8980

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aligos Therapeutics, Inc. Company profile

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aligos Therapeutics Inc revenues increased from $0K to $4.4M. Net loss increased 18% to $128.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 12% to $88.3M (expense), Stock-based Compensation in R&D increase from $1M to $7.6M (expense).

Industry: Biotechnology & Medical Research (NEC)

One Corporate Dr., 2Nd Floor
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

News

Bank of Japan Preview

The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.

09:40, 17 September 2024

FOMC Decision Preview

As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.

09:48, 16 September 2024

ECB Preview: cuts expected but the pace is uncertain

Markets expect the ECB to cut rates again in September, but how many more?

12:34, 11 September 2024

Market analysis: US CPI and PPI

Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.

07:56, 10 September 2024

Introducing Newsquawk: your new in-platform newsfeed

We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.

14:09, 20 August 2024

Jackson Hole Preview: All eyes on Powell and Gold

The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.

15:24, 19 August 2024

All eyes on inflation: US and UK CPI take centre stage

Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.

14:41, 13 August 2024

People also watch

XRP/USD

0.57 Price
-3.180% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,572.41 Price
+0.070% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0113%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

19,395.40 Price
-0.030% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

59,552.80 Price
-0.820% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 640,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading